Bromerguride

Bromerguride
Clinical data
Other names	2-Bromolisuride; 2-Br-LIS; Βromolisuride; Bromuride; ZK-95451; 3-(2-Βromo-9,10-didehydro-6-methyl-8α-ergolinyl)-1,1-diethylurea
Identifiers
	IUPAC name 3-[(6aR,9S)-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea;
CAS Number	83455-48-5;
PubChem CID	71266;
ChemSpider	64394;
UNII	HX58M2377W;
ChEMBL	ChEMBL2104211;
CompTox Dashboard (EPA)	DTXSID70232356 ;
Chemical and physical data
Formula	C20H25BrN4O
Molar mass	417.351 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C;
	InChI InChI=1S/C20H25BrN4O/c1-4-25(5-2)20(26)22-12-9-14-13-7-6-8-16-18(13)15(19(21)23-16)10-17(14)24(3)11-12/h6-9,12,17,23H,4-5,10-11H2,1-3H3,(H,22,26)/t12-,17+/m0/s1; Key:SBHNNNRQZGYOAU-YVEFUNNKSA-N;

Bromerguride (INNTooltip International Nonproprietary Name), also known as 2-bromolisuride, is an antidopaminergic and serotonergic agent of the ergoline group which was described as having atypical antipsychotic properties but was never marketed. It was the first antidopaminergic ergoline derivative to be discovered. The pharmacodynamic actions of bromerguride are said to be "reversed" relative to its parent compound lisuride, a dopaminergic agent.